UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)    November 18, 2004        
                                                 ------------------------


                            Interpharm Holdings, Inc.
               (Exact name of Registrant as specified in charter)

        Delaware                     0-22710                     13-3673965
 ---------------------------   ----------------------           ------------
(State or other jurisdiction  (Commission File Number)         (IRS Employer  
   of incorporation)                                         Identification No.)


                     69 Mall Drive, Commack, New York     11725
                -------------------------------------------------
               (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:    (631) 543-2800        
                                                       --------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
      CFR 240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


Item 5.02 Departure of Directors or Principal Officers; Appointment of Principal
          Officers.

      On November 18, 2004, the Board of Directors of Interpharm Holdings,  Inc.
("the Company") appointed Raj Sutaria as Chief Operating Officer of the Company.
Mr. Sutaria is also currently the Chief Operating  Officer of Interpharm,  Inc.,
the Company's wholly owned and sole operating  subsidiary,  and will continue in
that position.

      Raj Sutaria  graduated from  University of Colorado at Boulder in1997 with
B.B.A.  in  Marketing.  He  has  served  as  Production  Manager,   Director  of
Manufacturing,  Vice President and Chief Operating  Officer of Interpharm,  Inc.
since 1997.

      Raj  Sutaria  is an  owner/member  of  Sutaria  Family  Realty,  LLC.  The
Company's 100,000 square foot facility at 75 Adams Avenue in Hauppauge, New York
is owned by Sutaria  Family Realty,  LLC. The Company leases an entire  building
pursuant to a non-cancellable lease expiring in October,  2019, which houses the
Company's  manufacturing,  warehousing  and  some  of  the  Company's  executive
offices.  The current  annual lease  payments to the  landlord,  Sutaria  Family
Realty, LLC, are $480,000, plus property taxes, insurance, maintenance and other
expenses  related  to the leased  facility.  Upon a change in  ownership  of the
Company,  and every three  years  thereafter,  the annual  base rent,  which the
Company  believes  is below fair market  value,  will be adjusted to fair market
value, as determined by an independent appraisal.

      Raj  Sutaria  is the son of  Maganlal  K.  Sutaria,  the  Chairman  of the
Company's Board of Directors and the Company's  Chief Executive  Officer and the
nephew of Bhupatlal K. Sutaria, the Company's President.

      Mr.  Sutaria's  currently has an employment  agreement,  the term of which
ends December 31, 2007. The employment  agreement  provides for a base salary of
$160,000 per year,  which may be increased at the discretion of the Compensation
Committee of the Company's Board of Directors.

                                   Signatures

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                              INTERPHARM HOLDINGS, INC.


November 24, 2004                             By: /s/ George Aronson       
                                              ----------------------------------
                                              George Aronson
                                              Chief Financial Officer